VC: Novagali leads with 26M euros

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Novagali
France

26M euros
Third round

AGF Private Equity, Bernard Chauvin

The financing will support Phase III clinical trials and development of new ophthalmic products.

Bayhill Therapeutics
Palo Alto, CA

$15.8M
Second round

Current investors

With this additional capital, the company closed its second round at $51.2 million.

SkinMedica
Carlsbad, CA

$11.2M
Fifth round

Montagu Newhall Associates

SkinMedica develops products that treat dermatologic conditions and diseases.

Theranox
Philadelphia

$14M
First round

Quaker BioVentures, NewSpring Capital

The financing will fund clinical trials and commercialize the use of gaseous nitric oxide for the treatment of chronic wounds.